Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | SDHA | P31040 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20751435 | 1.00 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14580154 | 0.85 | MAOA (0.37) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14597136 | 0.85 | MAOA (0.37) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14580148 | 0.84 | IRAK4 (0.37) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14597135 | 0.84 | IRAK4 (0.37) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL18362138 | 0.84 | MTNR1A (0.40) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10252894 | 0.83 | F10 (0.41) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10249417 | 0.81 | ALDH1A1 (0.36) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL17108687 | 0.81 | F10 (0.38) | F10 | |
| SCHEMBL22387202 | 0.81 | F10 (0.38) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMB CHEMIE (DE) | 2019-04-18 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9133213-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2015-09-15 | — | — | US | disclosed |
| WO-2014191075-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2014-12-04 | — | — | WO | disclosed |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-1114819-B1 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN CO LLC (US) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | NR0B2, NR2C2, NR0B1 | MAOA 2965/4885MAOB 2611/4885LMNA 4493/4885 |
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | OXA1L, NQO2, NQO1 | MAOA 2294/4885MAOB 1677/4885LMNA 4306/4885 |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | MAOA 1595/4885MAOB 1428/4885LMNA 3615/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | MAOA 2966/4885MAOB 2570/4885LMNA 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.